Medacta International, an international orthopedics company headquartered in Castel San Pietro, Switzerland, recently received clearance from the U.S.’ Federal Drug Administration and Australia’s Therapeutic Goods Administration for two of its sports medicine products, the Mecta Lock PEEK Suture Anchor and the Mecta Screw PEEK Interference Screw.
Medacta Now Offers Sports Medicine Surgical Solutions
1 min read Premium comments
#medactaSecondary
The Mecta Lock PEEK Suture Anchor is intended to treat hip and shoulder instability by means of the refixation of the acetabular or glenoidal labrum to the bone during arthroscopic or open surgical approaches for fixation of suture (soft tissue) to bone in the shoulder and hip in the following procedures:
- Hip: acetabular labral repair; and
- Shoulder: glenoid labrum repair
According to Medacta’s IFU, the purpose of the Mecta Screw PEEK interference screws is to provide a suitable and secure intra-tunnel graft fixation in ligamentoplasty surgery for reconstructive treatment of ruptured anterior and posterior cruciate ligaments by means of auto- and allografts.
Medacta CEO Francesco Siccardi said, “Medacta is known for developing personalized orthopedic surgery solutions and providing a high level of support to the surgeons who adopt them. We look forward to applying our expertise to this new area, the next natural market for Medacta to enter following the success of our surgeon- and patient-friendly solutions across hip, knee, shoulder and spine.”
Medacta plans on growing its sports medicine portfolio in both the U.S. and Australia to offer surgeons working with athletes personalized, minimally invasive solutions.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.